Q-omics provides the consensus-scored METAP1D profile across patient tissues and cancer cell-line models. METAP1D expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, METAP1D is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, METAP1D RNA expression shows 20,572 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, COAD, and UVM as cancer lineages where METAP1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METAP1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METAP1D survival associations across molecular data types. METAP1D RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METAP1D RNA expression–survival associations across cancer types. High METAP1D expression shows unfavorable associations in THCA, ACC, LUAD and LIHC, but favorable associations in READ and BRCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for METAP1D RNA expression.
This table summarizes METAP1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for METAP1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METAP1D shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, LUAD, HNSC and LIHC. The COAD box plot shows higher METAP1D RNA expression in tumor versus normal tissue (log2 FC = +1.112, t-test p < 0.001).
This table shows molecular features associated with METAP1D in patient tissues and cancer cell lines. In patient samples, METAP1D shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, METAP1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and CNS.
